Todd Campbell

Todd Campbell

TMFEBCapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent articles

vaccine

Here's Why Dynavax Is Surging 6.1% Today

Enrollment has begun in an early stage coronavirus vaccine trial utilizing Dynavax's technology.


GettyImages-637107694

Blueprint Medicines Inks Deal With Roche Worth Up to $1.7 Billion

Roche is licensing commercial rights to Blueprint Medicines RET-inhibitor pralsetinib.


GettyImages-1138911813

Why InMode Shares Are Soaring 13.7% Today

The medical device maker's boosting its second-quarter guidance.


GettyImages-1178374751

Here's Why Retractable Technologies Is Skyrocketing 22% Today

The company's been awarded a multimillion-dollar government COVID-19 contract to expand production of needles and syringes.


GettyImages-1212440479

GlaxoSmithKline Inks New COVID-19 Vaccine Research Pact

Medicago is using GlaxoSmithKline's vaccine adjuvant in its clinical-stage COVID-19 vaccine.

GettyImages-637107694

Turning Point Therapeutics Licenses Its Lung Cancer Drug in China

Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.


GettyImages-910148024

Why Bellus Health Stock Tanked 69.2% Today

The company's lead drug has failed a phase 2 trial.


GettyImages-874899136

Why MEI Pharma Is Tanking 15.3% Today

A trial evaluating its most advanced drug has been discontinued because of a lack of efficacy.


GettyImages-1141354730

Why COVID-19 Vaccine Developer Dynavax Is Down 6.5% Today

Pfizer released intriguing data regarding its own COVID-19 vaccine.


GettyImages-1179979986

Why Translate Bio Crashed 21% Today

The clinical-stage vaccine developer, which is working on a COVID-19 vaccine candidate, announced it's selling more shares to the public.

GettyImages-1141354730

uniQure Inks $2 Billion Licensing Deal With CSL Behring

Agreement licenses the rights for a promising hemophilia B gene therapy.


GettyImages-186130825

Sanofi's Cost-Cutting Could Mean Big Job Losses

The company's management is considering a restructuring that may eliminate many positions.


GettyImages-637107694

EU Experts Recommend Approval of Gilead's COVID-19 Drug

A key advisory team has given remdesivir a thumbs up, clearing the way to an official green light for its use in Europe.


GettyImages-1186545957

Epizyme's Tazverik Wins FDA Approval to Treat Follicular Lymphoma

The label expansion for the drug significantly increases the number of patients to whom it can be prescribed.


GettyImages-1127055456

Biogen Loses Patent Case Over Its Best-Selling Drug

A judge has ruled in favor of Mylan's challenge to Tecfidera's patent protection.

GettyImages-1157294145

Why Iveric Bio Is Skyrocketing 24% Today

An upsized public offering has investors increasingly confident about its prospects.


GettyImages-1179979986

Why Pfizer's Shares Are Slipping 7.6% Today

The biopharma giant reported disappointing late-stage trial results for one of its best-selling medicines.


GettyImages-637107694

Dynavax Stock Soars 26.4% Today on COVID-19 Vaccine Hopes

The company's vaccine partner made positive comments about its progress today.


GettyImages-1179979986

Here's Why MacroGenics Is Tumbling 17.3% Today

Traders are exiting the stock as the ASCO 2020 conference gets underway.


motorcycle

Why Harley-Davidson's Shares Tumbled 5% This Morning

Analyst comments in Barron's are weighing on the motorcycle company today.